Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus

Journal of Diabetes Research

Volumn 2018, Issue , 2018, Pages

  Kamei, Shinji ^a   Iwamoto, Masahiro ^b   Kameyama, Miyuki ^b   Shimoda, Masashi ^a   Kinoshita, Tomoe ^a   Obata, Atsushi ^a   Kimura, Tomohiko ^a   Hirukawa, Hidenori ^a   Tatsumi, Fuminori ^a   Kohara, Kenji ^a   Nakanishi, Shuhei ^a   Mune, Tomoatsu ^a   Kaku, Kohei ^a   Kaneto, Hideaki ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Iwamoto Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; TOFOGLIFLOZIN; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BODY COMPOSITION; BODY FAT; BODY FLUID; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; DIABETIC PATIENT; DRUG EFFECT; EXTRACELLULAR FLUID; FAT MASS; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTRA-ABDOMINAL FAT; INTRACELLULAR WATER; JAPANESE (PEOPLE); MALE; MIDDLE AGED; MUSCLE MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; SARCOPENIA; SKELETAL MUSCLE; SOFT LEAN MASS; TOTAL BODY WATER; ASIAN CONTINENTAL ANCESTRY GROUP; ETHNOLOGY; GLUCOSE BLOOD LEVEL; IMPEDANCE; JAPAN; METABOLISM;

ASIAN CONTINENTAL ANCESTRY GROUP; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; ELECTRIC IMPEDANCE; FEMALE; GLUCOSIDES; HUMANS; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 85042630893     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2018/6470137     Document Type: Article

References (24)

1. Y. Ohtake, T. Sato, T. Kobayashi et al., "Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucosecotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes," Journal of Medicinal Chemistry, vol. 55, no. 17, pp. 7828-7840, 2012.
2. K. Kaku, H. Watada, Y. Iwamoto et al., "Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined phase 2 and 3 randomized, placebocontrolled, double-blind, parallel-group comparative study," Cardiovascular Diabetology, vol. 13, 2014.
3. M. Suzuki, K. Honda, M. Fukazawa et al., "Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice," The Journal of Pharmacology and Experimental Therapeutics, vol. 341, no. 3, pp. 692-701, 2012.
4. Y. Kim and A. R. Babu, "Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes," Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 5, pp. 313-327, 2012.
5. Y. Tanizawa, K. Kaku, E. Araki et al., "Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodiumglucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials," Expert Opinion on Pharmacotherapy, vol. 15, no. 6, pp. 749-766, 2014.
6. J. F. List, V. Woo, E. Morales, W. Tang, and F. T. Fiedorek, "Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes," Diabetes Care, vol. 32, no. 4, pp. 650-657, 2009.
7. E. M. Wright and E. Turk, "The sodium/glucose cotransport family SLC5," Pflügers Archiv, vol. 447, no. 5, pp. 510-518, 2004.
8. B. Thorens, "Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes," American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 270, no. 4, Part 1, pp. G541-G553, 1996.
9. O. Marsenic, "Glucose control by the kidney: an emerging target in diabetes," American Journal of Kidney Diseases, vol. 53, no. 5, pp. 875-883, 2009.
10. L. Zhang, Y. Feng, J. List, S. Kasichayanula, and M. Pfister, "Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight," Diabetes, Obesity & Metabolism, vol. 12, no. 6, pp. 510-516, 2010.
11. B. M. Prior, K. J. Cureton, C. M. Modlesky et al., "In vivo validation of whole body composition estimates from dualenergy X-ray absorptiometry," Journal of Applied Physiology, vol. 83, no. 2, pp. 623-630, 1997.
12. A. Pietrobelli, F. Rubiano, M. P. St-Onge, and S. B. Heymsfield, "New bioimpedance analysis system: improved phenotyping with whole-body analysis," European Journal of Clinical Nutrition, vol. 58, no. 11, pp. 1479-1484, 2004.
13. K. J. Shafer, W. A. Siders, L. K. Johnson, and H. C. Lukaski, "Validity of segmental multiple-frequency bioelectrical impedance analysis to estimate body composition of adults across a range of body mass indexes," Nutrition, vol. 25, no. 1, pp. 25-32, 2009.
14. M. Bolanowski and B. E. Nilsson, "Assessment of human body composition using dual-energy x-ray absorptiometry and bioelectrical impedance analysis," Medical Science Monitor, vol. 7, no. 5, pp. 1029-1033, 2001.
15. M. Malavolti, C. Mussi, M. Poli et al., "Cross-calibration of eight-polar bioelectrical impedance analysis versus dualenergy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21-82 years," Annals of Human Biology, vol. 30, no. 4, pp. 380-391, 2003.
16. K. J. Ellis, "Human body composition: in vivo methods," Physiological Reviews, vol. 80, no. 2, pp. 649-680, 2000.
17. N. Wattanapenpaiboon, W. Lukito, B. J. G. Strauss, B. H.-H. Hsu-Hage, M. L. Wahlqvist, and D. B. Stroud, "Agreement of skinfold measurement and bioelectrical impedance analysis (BIA) methods with dual energy X-ray absorptiometry (DEXA) in estimating total body fat in Anglo-Celtic Australians," International Journal of Obesity, vol. 22, no. 9, pp. 854-860, 1998.
18. A. S. Jackson, M. L. Pollock, J. E. Graves, and M. T. Mahar, "Reliability and validity of bioelectrical impedance in determining body composition," Journal of Applied Physiology, vol. 64, no. 2, pp. 529-534, 1988.
19. C. Vaché, P. Rousset, P. Gachon et al., "Bioelectrical impedance analysis measurements of total body water and extracellular water in healthy elderly subjects," International Journal of Obesity, vol. 22, no. 6, pp. 537-543, 1998.
20. I. Janssen, S. B. Heymsfield, and R. Ross, "Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability," Journal of the American Geriatrics Society, vol. 50, no. 5, pp. 889-896, 2002.
21. L. K. Chen, L. K. Liu, J. Woo et al., "Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia," Journal of the American Medical Directors Association, vol. 15, no. 2, pp. 95-101, 2014.
22. S. Hirose, S. Nakajima, Y. Iwahashi, A. Seo, T. Takahashi, and Y. Tamori, "Impact of the 8-week administration of tofogliflozin for glycemic control and body composition in Japanese patients with type 2 diabetes mellitus," Internal Medicine, vol. 55, no. 22, pp. 3239-3245, 2016.
23. Y. Terauchi, M. Tamura, M. Senda, R. Gunji, and K. Kaku, "Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): results of a 16-week randomized, double-blind, placebo-controlled multicentre trial," Diabetes, Obesity & Metabolism, vol. 19, no. 10, pp. 1397-1407, 2017.
24. T. Iizuka, K. Iemitsu, M. Takihata et al., "Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes: interim outcome of the ASSIGN-K study," Journal of Clinical Medicine Research, vol. 8, no. 2, pp. 116-125, 2016.